Anthranilic Acid Derivative - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Anthranilic Acid Derivative

The Experts below are selected from a list of 66 Experts worldwide ranked by ideXlab platform

Takayuki Noguchi – 1st expert on this subject based on the ideXlab platform

  • new Anthranilic Acid Derivative eants gs attenuates freund s complete adjuvant induced acute pain in rats
    Journal of Surgical Research, 2012
    Co-Authors: Kentaro Okuda, Naozumi Takeshima, Satoshi Hagiwara, Junji Takatani, Tetsuya Uchino, Takayuki Noguchi

    Abstract:

    Background Acute and chronic pain commonly accompany various clinical conditions such as contusion, fracture, osteoarthritis, peripheral neuropathy, and postherpetic neuralgia. Recent studies have found that antioxidative drugs can have analgesic effects. The present study tested the hypothesis that a new Anthranilic Acid Derivative, EAntS-GS, exerts antinociceptive effects on inflammatory pain in a rat model. Methods We induced subacute pain with a plantar injection of Freund’s complete adjuvant (FCA) in Sprague-Dawley rats. EAntS-GS (1 mg/kg subcutaneous injection or 1% application) was administered every 12 h beginning 24 h after FCA administration, and the plantar test was used to determine its effect on pain. Levels of myeloperoxidase, inducible nitric oxide synthase (iNOS), and protease activated receptor 2 (PAR2) were measured to elucidate the mechanism of action of EAntS-GS. Results EAntS-GS significantly reduced FCA-induced pain and myeloperoxidase, iNOS, and PAR2 levels. Our findings suggest that the new Anthranilic Acid Derivative, EAntS-GS, exerts antinociceptive effects, and that the mechanism involves iNOS and PAR2. Conclusion We conclude that EAntS-GS should be considered a new therapeutic tool to treat acute and chronic pain.

  • New Anthranilic Acid Derivative, EAntS-GS, Attenuates Freund’s Complete Adjuvant-Induced Acute Pain in Rats
    Journal of Surgical Research, 2011
    Co-Authors: Kentaro Okuda, Naozumi Takeshima, Satoshi Hagiwara, Junji Takatani, Tetsuya Uchino, Takayuki Noguchi

    Abstract:

    Background Acute and chronic pain commonly accompany various clinical conditions such as contusion, fracture, osteoarthritis, peripheral neuropathy, and postherpetic neuralgia. Recent studies have found that antioxidative drugs can have analgesic effects. The present study tested the hypothesis that a new Anthranilic Acid Derivative, EAntS-GS, exerts antinociceptive effects on inflammatory pain in a rat model. Methods We induced subacute pain with a plantar injection of Freund’s complete adjuvant (FCA) in Sprague-Dawley rats. EAntS-GS (1 mg/kg subcutaneous injection or 1% application) was administered every 12 h beginning 24 h after FCA administration, and the plantar test was used to determine its effect on pain. Levels of myeloperoxidase, inducible nitric oxide synthase (iNOS), and protease activated receptor 2 (PAR2) were measured to elucidate the mechanism of action of EAntS-GS. Results EAntS-GS significantly reduced FCA-induced pain and myeloperoxidase, iNOS, and PAR2 levels. Our findings suggest that the new Anthranilic Acid Derivative, EAntS-GS, exerts antinociceptive effects, and that the mechanism involves iNOS and PAR2. Conclusion We conclude that EAntS-GS should be considered a new therapeutic tool to treat acute and chronic pain.

Kentaro Okuda – 2nd expert on this subject based on the ideXlab platform

  • new Anthranilic Acid Derivative eants gs attenuates freund s complete adjuvant induced acute pain in rats
    Journal of Surgical Research, 2012
    Co-Authors: Kentaro Okuda, Naozumi Takeshima, Satoshi Hagiwara, Junji Takatani, Tetsuya Uchino, Takayuki Noguchi

    Abstract:

    Background Acute and chronic pain commonly accompany various clinical conditions such as contusion, fracture, osteoarthritis, peripheral neuropathy, and postherpetic neuralgia. Recent studies have found that antioxidative drugs can have analgesic effects. The present study tested the hypothesis that a new Anthranilic Acid Derivative, EAntS-GS, exerts antinociceptive effects on inflammatory pain in a rat model. Methods We induced subacute pain with a plantar injection of Freund’s complete adjuvant (FCA) in Sprague-Dawley rats. EAntS-GS (1 mg/kg subcutaneous injection or 1% application) was administered every 12 h beginning 24 h after FCA administration, and the plantar test was used to determine its effect on pain. Levels of myeloperoxidase, inducible nitric oxide synthase (iNOS), and protease activated receptor 2 (PAR2) were measured to elucidate the mechanism of action of EAntS-GS. Results EAntS-GS significantly reduced FCA-induced pain and myeloperoxidase, iNOS, and PAR2 levels. Our findings suggest that the new Anthranilic Acid Derivative, EAntS-GS, exerts antinociceptive effects, and that the mechanism involves iNOS and PAR2. Conclusion We conclude that EAntS-GS should be considered a new therapeutic tool to treat acute and chronic pain.

  • New Anthranilic Acid Derivative, EAntS-GS, Attenuates Freund’s Complete Adjuvant-Induced Acute Pain in Rats
    Journal of Surgical Research, 2011
    Co-Authors: Kentaro Okuda, Naozumi Takeshima, Satoshi Hagiwara, Junji Takatani, Tetsuya Uchino, Takayuki Noguchi

    Abstract:

    Background Acute and chronic pain commonly accompany various clinical conditions such as contusion, fracture, osteoarthritis, peripheral neuropathy, and postherpetic neuralgia. Recent studies have found that antioxidative drugs can have analgesic effects. The present study tested the hypothesis that a new Anthranilic Acid Derivative, EAntS-GS, exerts antinociceptive effects on inflammatory pain in a rat model. Methods We induced subacute pain with a plantar injection of Freund’s complete adjuvant (FCA) in Sprague-Dawley rats. EAntS-GS (1 mg/kg subcutaneous injection or 1% application) was administered every 12 h beginning 24 h after FCA administration, and the plantar test was used to determine its effect on pain. Levels of myeloperoxidase, inducible nitric oxide synthase (iNOS), and protease activated receptor 2 (PAR2) were measured to elucidate the mechanism of action of EAntS-GS. Results EAntS-GS significantly reduced FCA-induced pain and myeloperoxidase, iNOS, and PAR2 levels. Our findings suggest that the new Anthranilic Acid Derivative, EAntS-GS, exerts antinociceptive effects, and that the mechanism involves iNOS and PAR2. Conclusion We conclude that EAntS-GS should be considered a new therapeutic tool to treat acute and chronic pain.

Naozumi Takeshima – 3rd expert on this subject based on the ideXlab platform

  • new Anthranilic Acid Derivative eants gs attenuates freund s complete adjuvant induced acute pain in rats
    Journal of Surgical Research, 2012
    Co-Authors: Kentaro Okuda, Naozumi Takeshima, Satoshi Hagiwara, Junji Takatani, Tetsuya Uchino, Takayuki Noguchi

    Abstract:

    Background Acute and chronic pain commonly accompany various clinical conditions such as contusion, fracture, osteoarthritis, peripheral neuropathy, and postherpetic neuralgia. Recent studies have found that antioxidative drugs can have analgesic effects. The present study tested the hypothesis that a new Anthranilic Acid Derivative, EAntS-GS, exerts antinociceptive effects on inflammatory pain in a rat model. Methods We induced subacute pain with a plantar injection of Freund’s complete adjuvant (FCA) in Sprague-Dawley rats. EAntS-GS (1 mg/kg subcutaneous injection or 1% application) was administered every 12 h beginning 24 h after FCA administration, and the plantar test was used to determine its effect on pain. Levels of myeloperoxidase, inducible nitric oxide synthase (iNOS), and protease activated receptor 2 (PAR2) were measured to elucidate the mechanism of action of EAntS-GS. Results EAntS-GS significantly reduced FCA-induced pain and myeloperoxidase, iNOS, and PAR2 levels. Our findings suggest that the new Anthranilic Acid Derivative, EAntS-GS, exerts antinociceptive effects, and that the mechanism involves iNOS and PAR2. Conclusion We conclude that EAntS-GS should be considered a new therapeutic tool to treat acute and chronic pain.

  • New Anthranilic Acid Derivative, EAntS-GS, Attenuates Freund’s Complete Adjuvant-Induced Acute Pain in Rats
    Journal of Surgical Research, 2011
    Co-Authors: Kentaro Okuda, Naozumi Takeshima, Satoshi Hagiwara, Junji Takatani, Tetsuya Uchino, Takayuki Noguchi

    Abstract:

    Background Acute and chronic pain commonly accompany various clinical conditions such as contusion, fracture, osteoarthritis, peripheral neuropathy, and postherpetic neuralgia. Recent studies have found that antioxidative drugs can have analgesic effects. The present study tested the hypothesis that a new Anthranilic Acid Derivative, EAntS-GS, exerts antinociceptive effects on inflammatory pain in a rat model. Methods We induced subacute pain with a plantar injection of Freund’s complete adjuvant (FCA) in Sprague-Dawley rats. EAntS-GS (1 mg/kg subcutaneous injection or 1% application) was administered every 12 h beginning 24 h after FCA administration, and the plantar test was used to determine its effect on pain. Levels of myeloperoxidase, inducible nitric oxide synthase (iNOS), and protease activated receptor 2 (PAR2) were measured to elucidate the mechanism of action of EAntS-GS. Results EAntS-GS significantly reduced FCA-induced pain and myeloperoxidase, iNOS, and PAR2 levels. Our findings suggest that the new Anthranilic Acid Derivative, EAntS-GS, exerts antinociceptive effects, and that the mechanism involves iNOS and PAR2. Conclusion We conclude that EAntS-GS should be considered a new therapeutic tool to treat acute and chronic pain.